OBJECTIVES: To examine the validity of [(123)I]beta-CIT SPECT for monitoring the progression of dopaminergic degeneration in Parkinson's disease; to investigate the influence of short term treatment with D(2)receptor agonists on striatal [(123)I]beta-CIT binding; and to determine the sample size and frequency of SPECT imaging required to demonstrate a significant effect of a putative neuroprotective agent. METHODS: A group of 50 early stage Parkinson's disease patients was examined. Two SPECT imaging series were obtained, 12 months apart. The mean annual change in the ratio of specific to non-specific [(123)I]beta-CIT binding to the striatum, putamen, and caudate nucleus was used as the outcome measure. RESULTS: A decrease in [(123)I]beta-CIT binding ratios between the two images was found in all regions of interest. The average decrease in [(123)I]beta-CIT binding ratios was about 8% in the whole striatum, 8% in the putaminal region, and 4% in the caudate region. Comparison of scans done in nine patients under two different conditions-in the off state and while on drug treatment-showed no significant alterations in the expression of striatal dopamine transporters as measured using [(123)I]beta-CIT SPECT. Power analysis indicated that to detect a significant (p < 0.05) effect of a neuroprotective agent with 0.80 power and 30% of predicted protection within two years, 216 patients are required in each group when the effects are measured in the whole putamen. CONCLUSIONS: [(123)I]beta-CIT SPECT seems to be a useful tool to investigate the progression of dopaminergic degeneration in Parkinson's disease and may provide an objective method of measuring the effectiveness of neuroprotective treatments. Short term treatment with a D(2)agonist does not have a significant influence on [(123)I]beta-CIT binding to dopamine transporters. If the latter finding is replicated in larger groups of patients, it supports the suitability of [(123)I]beta-CIT SPECT for examining the progression of neurodegeneration in patients being treated with D(2)receptor agonists.
OBJECTIVES: To examine the validity of [(123)I]beta-CIT SPECT for monitoring the progression of dopaminergic degeneration in Parkinson's disease; to investigate the influence of short term treatment with D(2)receptor agonists on striatal [(123)I]beta-CIT binding; and to determine the sample size and frequency of SPECT imaging required to demonstrate a significant effect of a putative neuroprotective agent. METHODS: A group of 50 early stage Parkinson's diseasepatients was examined. Two SPECT imaging series were obtained, 12 months apart. The mean annual change in the ratio of specific to non-specific [(123)I]beta-CIT binding to the striatum, putamen, and caudate nucleus was used as the outcome measure. RESULTS: A decrease in [(123)I]beta-CIT binding ratios between the two images was found in all regions of interest. The average decrease in [(123)I]beta-CIT binding ratios was about 8% in the whole striatum, 8% in the putaminal region, and 4% in the caudate region. Comparison of scans done in nine patients under two different conditions-in the off state and while on drug treatment-showed no significant alterations in the expression of striatal dopamine transporters as measured using [(123)I]beta-CIT SPECT. Power analysis indicated that to detect a significant (p < 0.05) effect of a neuroprotective agent with 0.80 power and 30% of predicted protection within two years, 216 patients are required in each group when the effects are measured in the whole putamen. CONCLUSIONS: [(123)I]beta-CIT SPECT seems to be a useful tool to investigate the progression of dopaminergic degeneration in Parkinson's disease and may provide an objective method of measuring the effectiveness of neuroprotective treatments. Short term treatment with a D(2)agonist does not have a significant influence on [(123)I]beta-CIT binding to dopamine transporters. If the latter finding is replicated in larger groups of patients, it supports the suitability of [(123)I]beta-CIT SPECT for examining the progression of neurodegeneration in patients being treated with D(2)receptor agonists.
Authors: J Booij; G Tissingh; G J Boer; J D Speelman; J C Stoof; A G Janssen; E C Wolters; E A van Royen Journal: J Neurol Neurosurg Psychiatry Date: 1997-02 Impact factor: 10.154
Authors: J P Seibyl; K Marek; K Sheff; R M Baldwin; S Zoghbi; Y Zea-Ponce; D S Charney; C H van Dyck; P B Hoffer; R B Innis Journal: J Nucl Med Date: 1997-09 Impact factor: 10.057
Authors: Sean J Colloby; E David Williams; David J Burn; Jim J Lloyd; Ian G McKeith; John T O'Brien Journal: Eur J Nucl Med Mol Imaging Date: 2005-06-02 Impact factor: 9.236
Authors: D Salas-Gonzalez; Juan M Górriz; Javier Ramírez; Ignacio A Illán; Pablo Padilla; Francisco J Martínez-Murcia; Elmar W Lang Journal: Neuroinformatics Date: 2015-10
Authors: K Van Laere; L De Ceuninck; R Dom; J Van den Eynden; H Vanbilloen; J Cleynhens; P Dupont; G Bormans; A Verbruggen; L Mortelmans Journal: Eur J Nucl Med Mol Imaging Date: 2004-04-03 Impact factor: 9.236
Authors: Wooyoung Jang; Joong-Seok Kim; Jin Whan Cho; Young Hwan Kim; Ji Young Kim; Yun Young Choi; Hee-Tae Kim Journal: Neurol Sci Date: 2012-11-24 Impact factor: 3.307